Abbvie
ABBV----
Q1 FY2026 EarningsQ2 FY26 adjusted diluted EPS guidance was revised to $3.57 - $3.61, down from the previous range of $3.74 - $3.78. The $0.17 reduction reflects a $291M charge for acquired IPR&D and milestones incurred during the quarter. Full-year FY26 adjusted EPS guidance was similarly lowered to $13.91 - $14.11 (down from $14.08 - $14.28), bringing the total year-to-date impact of IPR&D expenses to $1,035M ($0.60 per share).
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Abbvie(ABBV) predict that the Revenue is 15 B (+12.43%), Beat estimate;the EBIT is 6.127 B (+8.48%), Miss estimate;the EPS is 0.39 (-45.83%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
15.00B12.43%
14.72B10.31%
+0.28B2.12%
EBITMiss expectations
6.13B8.48%
6.14B8.72%
-0.01B0.24%
EPSMiss expectations
0.3945.83%
1.25474.17%
-0.8640120.00%
Upcoming earnings report - FY2026 Q2 Earning Release
Available dateJul 31, 2026
Estimate Revenue16.77 B
Estimate EBIT8.158 B
Estimate EPS1.9366
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf